SAREUM HOLDINGS PLC (LON:SAR)

The company’s four development programmes: Chk1 Kinase, TYK2/JAK1 Autoimmune, TYK2/JAK1 Cancer and Aurora+FLT3 Kinase. Chechpoint Kinase 1 (Chk1) program is the most advance programme that shows strong potency in multiple cancer models.

https://kalkinemedia.com/uk/companies/lon-sar